{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    28,
    29,
    30,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47
  ],
  "modelUsed": "gemini-2.5-pro",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Palbociclib",
        "type": {
          "id": "4c538623-ecdb-4afd-87f3-67a48e849f9f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "694e6442-998d-4062-a1e3-3d3f2327074b",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "PD-0332991, an orally active reversible inhibitor of Cyclin-Dependent Kinase (CDK) 4/6.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "5665870b-3df6-493b-81c0-95a221158ff4",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "b66585e8-bf51-444b-9520-ff4b52ece10e",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Placebo matching palbociclib.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Fulvestrant",
        "type": {
          "id": "dfde11b7-588b-477b-8bf9-63158d65b7a1",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "6ed88265-fef4-4898-8c8b-e9c665d20bc8",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Faslodex®, a competitive estrogen receptor (ER) antagonist, administered to all patients in both treatment arms.",
        "productIds": [
          "prod_3"
        ],
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Goserelin",
        "type": {
          "id": "68a08a23-f54e-4ea3-994e-d272c6691248",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "40cb9490-a0ba-4e59-a089-6937bae7a40f",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Zoladex® or generic, a Luteinizing Hormone-Releasing Hormone (LHRH) agonist, administered to all pre- and peri-menopausal women in both treatment arms.",
        "productIds": [
          "prod_4"
        ],
        "administrationIds": [
          "admin_4"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Palbociclib",
        "administrableDoseForm": {
          "id": "1468008e-1842-41af-8802-265eb1e98245",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "b83477e3-b4df-488d-b417-0d31dc15c33b",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "617ee459-08a1-4241-971b-04c69e272749",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "125 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Pfizer"
      },
      {
        "id": "prod_2",
        "name": "Placebo",
        "administrableDoseForm": {
          "id": "d6767fbd-977f-4267-af68-836862dd2b18",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "1dd30e9c-fadd-49b5-b78f-48ed4640ce48",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "be22b03f-91ed-4b82-8900-c2f07dfe0669",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Matching 125 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Pfizer"
      },
      {
        "id": "prod_3",
        "name": "Fulvestrant (Faslodex®)",
        "administrableDoseForm": {
          "id": "3bef9f32-a161-4620-84d6-4118f5fcdfd1",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "1b23d0cf-70b8-4efa-b8c9-e6a35554c98f",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "34d487ff-4e6b-4f3c-b69d-be46cbc20c33",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "500 mg",
        "substanceIds": [
          "sub_3"
        ]
      },
      {
        "id": "prod_4",
        "name": "Goserelin (Zoladex®)",
        "administrableDoseForm": {
          "id": "e7fd8122-a975-4f33-875c-46017e70ce05",
          "code": "C17998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Unknown",
          "standardCode": {
            "id": "7e64e165-c10e-46fc-a279-e91aae20a8f9",
            "code": "C17998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Unknown",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "38ab5f15-4bd5-4590-b5ca-c69cefd7255f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "3.6 mg"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Palbociclib 125 mg",
        "instanceType": "Administration",
        "dose": "125 mg",
        "doseFrequency": "once daily on Days 1 to 21 of each 28-day cycle (3 weeks on, 1 week off)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
      },
      {
        "id": "admin_2",
        "name": "Placebo",
        "instanceType": "Administration",
        "dose": "Matching placebo",
        "doseFrequency": "once daily on Days 1 to 21 of each 28-day cycle (3 weeks on, 1 week off)",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
      },
      {
        "id": "admin_3",
        "name": "Fulvestrant 500 mg",
        "instanceType": "Administration",
        "dose": "500 mg",
        "doseFrequency": "On Days 1 and 15 of Cycle 1, then every 28 days thereafter.",
        "route": {
          "code": "Intramuscular",
          "codeSystem": "USDM",
          "decode": "Intramuscular"
        },
        "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
      },
      {
        "id": "admin_4",
        "name": "Goserelin 3.6 mg",
        "instanceType": "Administration",
        "dose": "3.6 mg",
        "doseFrequency": "every 28 days",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "For the duration of the trial for pre- and peri-menopausal women. Must be started at least 4 weeks prior to randomization."
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Palbociclib",
        "instanceType": "Substance",
        "description": "PD-0332991"
      },
      {
        "id": "sub_2",
        "name": "Fulvestrant",
        "instanceType": "Substance"
      },
      {
        "id": "sub_3",
        "name": "Goserelin",
        "instanceType": "Substance"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 4,
      "productCount": 4,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Palbociclib",
        "role": "Investigational Product",
        "description": "PD-0332991, an orally active reversible inhibitor of Cyclin-Dependent Kinase (CDK) 4/6."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Placebo matching palbociclib."
      },
      {
        "name": "Fulvestrant",
        "role": "Background Therapy",
        "description": "Faslodex®, a competitive estrogen receptor (ER) antagonist, administered to all patients in both treatment arms."
      },
      {
        "name": "Goserelin",
        "role": "Background Therapy",
        "description": "Zoladex® or generic, a Luteinizing Hormone-Releasing Hormone (LHRH) agonist, administered to all pre- and peri-menopausal women in both treatment arms."
      }
    ],
    "products": [
      {
        "name": "Palbociclib",
        "doseForm": "Capsule",
        "strength": "125 mg",
        "manufacturer": "Pfizer"
      },
      {
        "name": "Placebo",
        "doseForm": "Capsule",
        "strength": "Matching 125 mg",
        "manufacturer": "Pfizer"
      },
      {
        "name": "Fulvestrant (Faslodex®)",
        "doseForm": "Injection",
        "strength": "500 mg",
        "manufacturer": null
      },
      {
        "name": "Goserelin (Zoladex®)",
        "doseForm": "Implant",
        "strength": "3.6 mg",
        "manufacturer": null
      }
    ],
    "substances": [
      {
        "name": "Palbociclib",
        "description": "PD-0332991"
      },
      {
        "name": "Fulvestrant",
        "description": null
      },
      {
        "name": "Goserelin",
        "description": null
      }
    ],
    "administrations": [
      {
        "name": "Palbociclib 125 mg",
        "dose": "125 mg",
        "frequency": "once daily on Days 1 to 21 of each 28-day cycle (3 weeks on, 1 week off)",
        "route": "Oral",
        "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
      },
      {
        "name": "Placebo",
        "dose": "Matching placebo",
        "frequency": "once daily on Days 1 to 21 of each 28-day cycle (3 weeks on, 1 week off)",
        "route": "Oral",
        "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
      },
      {
        "name": "Fulvestrant 500 mg",
        "dose": "500 mg",
        "frequency": "On Days 1 and 15 of Cycle 1, then every 28 days thereafter.",
        "route": "Intramuscular",
        "duration": "Until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent."
      },
      {
        "name": "Goserelin 3.6 mg",
        "dose": "3.6 mg",
        "frequency": "every 28 days",
        "route": "Subcutaneous",
        "duration": "For the duration of the trial for pre- and peri-menopausal women. Must be started at least 4 weeks prior to randomization."
      }
    ],
    "devices": []
  }
}